Orphan drug designation is available for drugs already approved for another disease or condition or for experimental drugs that have not been previously approved.

During the workshop, participants will propose a specific drug for a specific rare disease and work on an orphan designation application to submit to the FDA at the conclusion of the workshop.

Orphan drug status provides the company with financial incentives to promote the development of a drug to treat a rare disease or condition.